Sorrento Therapeutics (NASDAQ:SRNE) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report report published on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

Shares of NASDAQ SRNE opened at $0.02 on Tuesday. Sorrento Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.42. The firm has a fifty day moving average price of $0.02 and a 200-day moving average price of $0.05.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.